Danaher Pricing Strategy Key To Navigating Tariff Challenges: Analyst – Danaher (NYSE:DHR)

Danaher Corp DHR on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the consensus of $5.59 billion. 

Non-GAAP core revenue was flat compared to the expectations of a decline by a low-single-digit percentage year-over-year in the first quarter.

Danaher reported second-quarter adjusted EPS of $1.88, down from $1.92 a year ago, beating the consensus of $1.64.

For FY2025, Danaher initiated adjusted EPS guidance of $7.60 to $7.75 vs. the consensus of$7.68. The company said, “We wanted to make sure everyone had an anchor point and believe having an adjusted EPS guide provides more clarity.”

Goldman Sachs writes, “DHR posted a solid quarter with Bioprocessing above expectations showing sequential order growth and book-to-bill above 1x in line with our view that Bioprocessing remains one of the more attractive areas of exposure for Tools investors. As expected, they posted a solid beat in respiratory, which should help offset some of the China IVD headwinds.”

Also Read: Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence

“Also, they believe they can mitigate their own tariff impact through manufacturing flexibility and pricing, providing some comfort to investors for the sector as we start earnings season,” analyst Matthew Sykes writes.

Goldman Sachs maintains the Buy rating on Danaher, with a price target of $260.

Goldman Sachs expects most Tools companies this quarter to beat their first-quarter earnings but stick to their full-year guidance, essentially taking the win without raising expectations.

William Blair writes, “Despite the uncertain macro backdrop, Danaher delivered a solid first-quarter print including a healthy top-line beat driven by outperformance in bioprocessing.”

Analyst Matt Larew writes that first-quarter earnings align with what we expected based on our earlier checks. These checks showed that the bioprocessing market is steadily recovering. Analyst Larew believes the company’s decision to keep its core guidance unchanged—and even slightly raise its bioprocessing growth outlook—should be seen as a positive sign, especially given the current economic conditions.

William Blair maintains the Outperform rating.

Price Action: DHR stock is up 4.32% at $192.98 at the last check Tuesday.

Read next:

Images: Shutterstock